Fosun Pharma 2025 Results: Innovation Revenue Surges as Global Footprint Expands
Key Takeaways
- Fosun Pharma (2196.HK) reported its 2025 annual results, highlighting a significant shift toward innovative drug revenue and successful international commercialization of its biosimilar portfolio.
- The company's strategic focus on oncology and high-value therapeutics continues to drive growth despite a challenging global macroeconomic environment.
Mentioned
Key Intelligence
Key Facts
- 1Innovative drug revenue now accounts for over 35% of total pharmaceutical manufacturing turnover, a record high for the company.
- 2Hanquyou (trastuzumab biosimilar) is now approved in 40+ countries and regions, including the US and EU.
- 3R&D investment was maintained at approximately 15-20% of pharmaceutical manufacturing revenue to support 70+ clinical projects.
- 4Hansizhuang (serplulimab) achieved significant market share as the first anti-PD-1 mAb for first-line small cell lung cancer (SCLC).
- 5Yescarta (Yi Kai Da) commercialization in China reached new patient enrollment milestones via the Kite Pharma joint venture.
Who's Affected
Analysis
Fosun Pharma's 2025 annual results, announced on March 24, 2026, underscore a pivotal transformation from a traditional pharmaceutical conglomerate into a global innovation-driven healthcare leader. The results highlight a sustained double-digit growth in innovative drug revenue, which now accounts for a record-high percentage of the company's total pharmaceutical manufacturing turnover. This shift is primarily driven by the commercial success of its flagship oncology treatments, including the PD-1 inhibitor Hansizhuang (serplulimab) and the trastuzumab biosimilar Hanquyou, which have both secured significant market share in China and expanded their footprint internationally. The company's ability to transition its portfolio toward high-margin, innovative therapies is a testament to its long-term R&D strategy and its capacity to navigate the rigorous regulatory pathways of major global markets.
The 2025 performance reflects the success of Fosun Pharma's "Global Innovation" and "Global Operation" strategy. A key highlight of the year was the continued internationalization of its biosimilar portfolio. Hanquyou, developed by its subsidiary Shanghai Henlius Biotech, has now been approved in over 40 countries and regions, including the United States and the European Union, making it one of the most successful Chinese-developed biologics globally. This global reach is further bolstered by Gland Pharma, the company's Indian subsidiary, which continues to serve as a critical engine for its global generic and CDMO business. Despite facing pricing pressures in the U.S. market, Gland Pharma's diversified manufacturing capabilities and strong compliance record have allowed it to maintain a competitive edge in the injectable drugs segment.
Fosun Pharma maintained its R&D intensity, with expenditures consistently representing approximately 15-20% of its pharmaceutical manufacturing revenue.
Investment in research and development (R&D) remained a cornerstone of the 2025 results. Fosun Pharma maintained its R&D intensity, with expenditures consistently representing approximately 15-20% of its pharmaceutical manufacturing revenue. This investment is fueling a robust pipeline of over 70 projects in various stages of clinical development, with a strategic focus on oncology, immunology, and rare diseases. The company's commitment to cutting-edge technologies is evident in its progress with antibody-drug conjugates (ADCs), cell therapies, and mRNA-based vaccines and therapeutics. Notably, the commercialization of Yescarta (Yi Kai Da), the first CAR-T cell therapy approved in China through its joint venture with Kite Pharma, has established a high-barrier-to-entry leadership position in the hematological oncology market. The company is also actively exploring the potential of its mRNA platform beyond COVID-19, targeting other infectious diseases and oncology indications.
What to Watch
However, the 2025 results also reveal the challenges of a complex regulatory and competitive landscape. While innovative drugs are surging, the company's traditional generic business continues to face headwinds from China's volume-based procurement (VBP) policy, which has compressed margins on mature products. To mitigate this, Fosun Pharma has aggressively optimized its product mix and improved operational efficiency through digital transformation and supply chain integration. The company's healthcare services and medical devices segments also showed resilience, with a focus on high-end medical equipment and specialized hospital services providing a diversified revenue stream. The medical devices segment, in particular, has benefited from the localization of Da Vinci surgical systems and the expansion of its diagnostic imaging portfolio.
Looking forward, Fosun Pharma's trajectory will be defined by its ability to navigate the "innovation-to-commercialization" gap in international markets. While the U.S. and EU approvals for its biosimilars are significant milestones, the company must now execute on its commercialization strategy in these highly competitive regions, often through strategic partnerships with local players. Investors and industry analysts will be closely watching the progress of its next-generation innovative assets, particularly its ADC platform and its expansion into the metabolic disease space, including GLP-1 receptor agonists. As the global biotech sector faces a period of consolidation and heightened scrutiny on R&D productivity, Fosun Pharma's diversified portfolio, strong cash flow from mature assets, and global operational capabilities position it as a resilient player in the evolving pharmaceutical landscape.
Timeline
Timeline
ADC Platform Milestone
First internally developed ADC candidate enters Phase II clinical trials.
CAR-T Expansion
Yescarta receives expanded indication approval for second-line treatment in China.
US FDA Approval
Key biosimilar assets receive final marketing authorization for the US market.
2025 Annual Results
Fosun Pharma officially releases its full-year financial performance for 2025.
Sources
Sources
Based on 2 source articles- manilatimes.netFosun Pharma Announces 2025 Annual ResultsMar 24, 2026
- thailand-business-news.comFosun Pharma Announces 2025 Annual Results - Thailand Business NewsMar 24, 2026
How we covered this story
Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled biotech-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |